miR-155, miR-21, and let-7a Expressions in MCF-10A and MCF-7 Cell Lines after Low to High Dose Irradiation.
MiR-155
MiR-21
Breast Cancer
Ionizing Radiation
Let-7a
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
09
2020
accepted:
08
06
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
ppublish
Résumé
Ionizing radiation is a tremendous risk factor for cancer development. MicroRNAs (miRNAs) are regulators that utilize cell pathways, which are implicated in human cancer prognosis. In addition, miRNAs respond to anti-cancer therapy and proliferation after irradiation. However, the changes in miRNA expression profiles in response to irradiation have not been comprehensively analysed. The present study was designed to assess potential changes that occur in miRNA expression following irradiation. In this experimental study, we used quantitative real-time polymerase chain reaction (qRTPCR) to measure the expressions of miR-155, miR-21, and let-7a in MCF-10A (normal breast cells) and MCF-7 (breast cancer cells) six hours after the cells were exposed to five different irradiation doses (50, 100, 400, 2000, and 4000 mGY). After irradiation from the low to high doses, we observed an upsurge in miR-155 (more than 100%) expression and reduction in let-7a (more than 87%) expression. However, there was an increase and a reduction in miR-21 expression (more than 100%). Irradiation can play an important role in cancer development in normal breast cells (MCF-10A) at low dose irradiation. However, the results showed little difference at high doses of radiation.
Identifiants
pubmed: 34837680
doi: 10.22074/cellj.2021.7411
pmc: PMC8588820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
532-537Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
Breast Cancer. 2018 Mar;25(2):198-205
pubmed: 29101635
RNA. 2008 Nov;14(11):2348-60
pubmed: 18812439
Curr Opin Cell Biol. 2009 Jun;21(3):470-9
pubmed: 19411171
Mol Cell. 2008 Oct 24;32(2):276-84
pubmed: 18951094
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43
pubmed: 22736789
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Adv Cancer Res. 2017;135:1-24
pubmed: 28882219
J Assoc Genet Technol. 2011;37(1):21-8
pubmed: 21430352
Clin Cancer Res. 2005 Oct 15;11(20):7392-7
pubmed: 16243812
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5
pubmed: 17600087
Cancer Res. 2009 Oct 15;69(20):8157-65
pubmed: 19826040
Cell. 2007 Dec 14;131(6):1109-23
pubmed: 18083101
J Surg Oncol. 2012 Sep 1;106(3):260-6
pubmed: 22105810
Nat Rev Cancer. 2009 Apr;9(4):293-302
pubmed: 19262572
PLoS One. 2010 May 14;5(5):e10630
pubmed: 20498843
Oncogene. 2012 May 24;31(21):2601-13
pubmed: 21963855
BMC Cancer. 2009 May 28;9:163
pubmed: 19473551
Clin Chem. 2013 Dec;59(12):1811-2
pubmed: 23462030
Cell. 2011 Nov 23;147(5):1066-79
pubmed: 22118463
J Res Med Sci. 2017 Dec 26;22:130
pubmed: 29387117
Mol Oncol. 2010 Jun;4(3):230-41
pubmed: 20537965
Nat Med. 2011 Sep 25;17(10):1275-82
pubmed: 21946536
Pathol Oncol Res. 2017 Oct;23(4):707-715
pubmed: 28070818
DNA Cell Biol. 2010 Sep;29(9):553-61
pubmed: 20380575
PLoS One. 2011;6(10):e24429
pubmed: 22022355
Cancer Res. 2010 Apr 15;70(8):3119-27
pubmed: 20354188
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4536-41
pubmed: 24616504
Lung Cancer. 2013 Aug;81(2):167-73
pubmed: 23683497
J Biol Chem. 2010 Jun 4;285(23):17869-79
pubmed: 20371610
Ann Surg Treat Res. 2017 Feb;92(2):55-66
pubmed: 28203552
Cell. 2010 Feb 19;140(4):445-9
pubmed: 20178735